ROCKVILLE, Md.--(BUSINESS WIRE)--
BIOQUAL, Inc. (OTC Pink: BIOQ) ():
|
Six Months Ended
|
Three Months Ended
|
||||||||||
|
|
2020 |
|
|
2019 |
|
|
2020 |
|
|
2019 |
|
Revenue
|
$ |
28,486,183 |
$ |
21,290,838 |
$ |
13,565,708 |
$ |
11,222,962 |
||||
Income Before Income Tax
|
$ |
4,562,602 |
$ |
3,132,524 |
$ |
2,065,614 |
$ |
1,258,041 |
||||
Net Income
|
$ |
3,228,002 |
$ |
2,216,324 |
$ |
1,461,414 |
$ |
891,841 |
||||
Basic Earnings per Share |
|
|
|
|
|
|
|
|
||||
of Common Stock |
$ |
3.61 |
$ |
2.48 |
$ |
1.63 |
$ |
1.00 |
||||
|
||||||||||||
Diluted Earnings per Share |
|
|
|
|
|
|
|
|
||||
of Common Stock |
$ |
3.61 |
$ |
2.48 |
$ |
1.63 |
$ |
1.00 |
||||
|
||||||||||||
Weighted Average |
|
|
|
|
|
|
|
|
||||
Number of Shares Outstanding |
|
|
|
|
|
|
|
|
||||
For Basic Earnings Per Share |
|
893,694 |
|
893,416 |
|
893,976 |
|
893,416 |
||||
|
||||||||||||
Weighted Average |
|
|
|
|
|
|
|
|
||||
Number of Shares Outstanding |
|
|
|
|
|
|
|
|
||||
For Diluted Earnings Per Share |
|
893,694 |
|
893,838 |
|
893,976 |
|
893,838 |
||||
|
||||||||||||
For more detail related to the fiscal year 2021 unaudited second quarter results, please visit our web site at .
Statements herein that are not descriptions of historical facts are forward-looking and subject to risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors including risks relating to the ability to continue to extend current government contracts; the Company’s ability to obtain new government or commercial contracts; continued demand for the use of animal models in scientific research; the Company’s ability to perform under its contracts in accordance with the requirements of the contracts; the actual costs incurred in performing the Company’s contracts and its ability to manage its costs, including its capital expenditures; dependence on third parties; future capital needs; the ability to fund its capital needs through the use of its cash on hand and line of credit; and the future availability and cost of financing/capital sources to the Company.
View source version on businesswire.com:
